This site is intended for U.S. healthcare professionals.
Category 1† Recommendation for encorafenib in combination with binimetinib as a first-line systemic therapy option for patients with metastatic or unresectable cutaneous melanoma with a BRAF V600–activating mutation included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cutaneous Melanoma, Version 1.2022.5
14.9 MONTHS (n=192; 95% CI: 11.0-18.5)
BRAFTOVI + MEKTOVI
7.3 MONTHS (n=191; 95% CI: 5.6-8.2)
Primary Analysis: (HR=0.54 [95% Cl: 0.41-0.71], P<0.0001)
In the metastatic setting, 5% of patients receiving BRAFTOVI + MEKTOVI in the COLUMBUStrial had prior treatment with immunotherapy.4
NCCN Guidelines® include encorafenib (BRAFTOVI) in combination with binimetinib (MEKTOVI) as one of the Category 1† options, among other recommended regimens, for patients with metastatic or unresectable melanoma who harbor a BRAF V600-activating mutation5
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Melanoma: Cutaneous V.2.2023.5
Over 8,500 adult patients with unresectable or metastatic melanoma with a BRAF V600E/K mutation have been prescribed BRAFTOVI + MEKTOVI since FDA approval4‡
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) are kinase inhibitors indicated for use in combination for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma.